Nami Therapeutics

08/14/2020

Connect with us on LinkedIn!

The limitations of current cancer nanomedicines include low tumor delivery efficiency, no significant benefit in treatment efficacy, cancer relapse when...

08/10/2020

"It's exciting that the whole research team identified this new mechanism to effectively inhibit leukemia stem cells," Lu says. "We are happy to see that our proprietary nanoparticle delivery system has such potential to help patients."

UConn associate professor of pharmaceutics Xiuling Lu, along with professor of chemistry Rajeswari M. Kasi, was part of a team that recently published a paper in Nature Cell Biology finding a commonly used chemotherapy drug may be repurposed as a treatment for resurgent or chemotherapy-resistant leu...

08/04/2020

Dr. Xiuling Liu continues to make endless efforts in contributing to cancer research and finding new solutions to save patient lives. An article she helped write titled "Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells" was published in Nature Cell Biology.

Targeting resistant stem cells in leukaemia, Perry et al. show that doxorubicin at low doses decreases Akt-mediated β-catenin activity, downregulates expression of multiple immune-checkpoint genes and dampens tumorigenesis of leukaemia stem cells.

07/30/2020

The "Nami" in our company name comes from the Mandarin word for “nano." Read more about our company origins and the innovative nanotechnology we are developing to advance cancer therapy in this article published in UConn Today.

Nami Therapeutics, a collaboration by UConn and the University of North Carolina, is developing a tumor-specific radioactive therapy designed to specifically target ovarian cancer.

07/28/2020

Dr. Xiuling Liu's article "Engineering Multifunctional Gold Decorated Dendritic Mesoporous Silica/Tantalum Oxide Nanoparticles for Intraperitoneal Tumor-Specific Delivery” describes the promising research she has done and continues to do in developing radiotherapeutics. Check out UConn Today's highlight on her work!

A technique for using radiosensitizers and image-guided radiotherapy holds promise for the treatment of ovarian cancer, one of the most deadly cancers affecting women today.

07/26/2020

Nami Business Advisor: Jeffrey C. Miller, MBA

Jeff has over 24 years in the bio/pharmaceutical industry with large, mid-size, and small companies such as Eli Lilly, Boehringer Ingelheim, Merck Serono, Alexion, and Alnylam. Starting in commercial functions, he expanded his career into broad, complex roles in general management and international strategy, leading both mature and start-up businesses across numerous therapeutic areas spanning rare diseases, oncology, primary care, and specialty care.

07/25/2020

Nami Clinical Advisor: Andrew Salner, M.D.

Dr. Salner serves as Medical Director at the Hartford Health Care Cancer Institute at Hartford Hospital. He has more than 40 years of clinical experience in Radiation Oncology and was the past President of the American Cancer Society in Connecticut and Chair of Nuclear/Radiologic Response Committee, ASTRO. He has achieved many awards including the American Cancer Society George Sheehan Humanitarian Award, the St. George Medal, and the Lane Adams Quality of Life Award.

07/24/2020

Nami Clinical Advisor: Ron Pion, M.D.

Dr. Pion served on the faculty of the University of Washington and the University of Hawaii and became a pioneer in the area of medical telecommunications, working in that area for more than 30 years. He served as a full-time medical correspondent for KNBC television in Los Angeles prior to founding the Hospital Satellite Network, the nation's first daily satellite-delivered television service providing programming for hospital-based health professionals and patients. He is a Clinical Professor at the UCLA School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists.

07/23/2020

Nami Head of R&D: David Worthen, Ph.D., J.D.

Dr. Worthen has years of experience serving as senior scientist, project manager, group leader, and academic investigator in pharmaceuticals, polymers, veterinary and other consumer products, contract research, and in other regulated industries at Bristol-Myers Squibb, Coldstream Laboratories, and Yaupon Therapeutics, Inc. He also served as a prior faculty member at the University of Rhode Island (URI) in both pharmaceutical science and in chemical engineering and is familiar with both GMP manufacturing of pharmaceutical products and FDA regulations.

07/22/2020

Nami President (Business): Ruobing Xia, MBA

Ruobing is responsible for Nami's global strategy, business development, and commercial operations. She has over 20 years of experience in big pharma (Eli Lilly & Boehringer Ingelheim) managing hundred million dollar product launches and promotions, developing sales and marketing strategies, and generating licensing deals with BD expertise. She is also a founder and board member of several startup companies.

07/21/2020

Nami Chief Scientific Officer: Michael Jay, Ph.D.

Dr. Jay has over 37 years of experience in drug development and formulations and imaging agents and was the former director of an FDA-registered cGMP manufacturing facility. An entrepreneur, he has founded five companies (one of which is currently moving to clinical trials). He also serves as Chair of the Division of Pharmacoengineering and Molecular Pharmaceutics at the University of North Carolina Eshelman School of Pharmacy and holds a distinguished professorship.